News | October 30, 2023
Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
The companies plan to start a pivotal Phase 3 trial in the coming months
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
Subscribe To Our Newsletter & Stay Updated
